A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men With D0 Prostate Cancer Following Limited Androgen Ablation.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2012
At a glance
- Drugs Prostate cancer vaccine (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Aug 2012 Kael-GemVax added as company and lead trial centre as reported by ClinicalTrials.gov.
- 08 Aug 2012 Planned End Date 1 Sep 2012 added as reported by ClinicalTrials.gov.